TY - JOUR
T1 - Proteins selected in Leishmania (Viannia) braziliensis by an immunoproteomic approach with potential serodiagnosis applications for tegumentary leishmaniasis
AU - Duarte, Mariana C.
AU - Pimenta, Daniel C.
AU - Menezes-Souza, Daniel
AU - Magalhães, Rubens D.M.
AU - Diniz, João L.C.P.
AU - Costa, Lourena E.
AU - Chávez-Fumagalli, Miguel A.
AU - Lage, Paula S.
AU - Bartholomeu, Daniela C.
AU - Alves, Maria Julia M.
AU - Fernandes, Ana Paula
AU - Soto, Manuel
AU - Tavares, Carlos A.P.
AU - Gonçalves, Denise U.
AU - Rocha, Manoel O.C.
AU - Coelho, Eduardo A.F.
N1 - Publisher Copyright:
Copyright © 2015, American Society for Microbiology.
PY - 2015/11
Y1 - 2015/11
N2 - The serodiagnosis of human tegumentary leishmaniasis (TL) presents some problems, such as the low level of antileishmanial antibodies found in most of the patients, as well as the cross-reactivity in subjects infected by other trypanosomatids. In the present study, an immunoproteomic approach was performed aimed at identification of antigens in total extracts of stationaryphase promastigote and amastigote-like forms of Leishmania (Viannia) braziliensis using sera from TL patients. With the purpose of reducing the cross-reactivity of the identified proteins, spots recognized by sera from TL patients, as well as those recognized by antibodies present in sera from noninfected patients living in areas where TL is endemic and sera from Chagas disease patients, were discarded. Two Leishmania hypothetical proteins and 18 proteins with known functions were identified as antigenic. The study was extended with some of them to validate the results of the immunoscreening. The coding regions of five of the characterized antigens (enolase, tryparedoxin peroxidase, eukaryotic initiation factor 5a, β-tubulin, and one of the hypothetical proteins) were cloned in a prokaryotic expression vector, and the corresponding recombinant proteins were purified and evaluated for the serodiagnosis of TL. The antigens presented sensitivity and specificity values ranging from 95.4 to 100% and 82.5 to 100%, respectively. As a comparative antigen, a preparation of Leishmania extract showed sensitivity and specificity values of 65.1 and 57.5%, respectively. The present study has enabled the identification of proteins able to be employed for the serodiagnosis of TL.
AB - The serodiagnosis of human tegumentary leishmaniasis (TL) presents some problems, such as the low level of antileishmanial antibodies found in most of the patients, as well as the cross-reactivity in subjects infected by other trypanosomatids. In the present study, an immunoproteomic approach was performed aimed at identification of antigens in total extracts of stationaryphase promastigote and amastigote-like forms of Leishmania (Viannia) braziliensis using sera from TL patients. With the purpose of reducing the cross-reactivity of the identified proteins, spots recognized by sera from TL patients, as well as those recognized by antibodies present in sera from noninfected patients living in areas where TL is endemic and sera from Chagas disease patients, were discarded. Two Leishmania hypothetical proteins and 18 proteins with known functions were identified as antigenic. The study was extended with some of them to validate the results of the immunoscreening. The coding regions of five of the characterized antigens (enolase, tryparedoxin peroxidase, eukaryotic initiation factor 5a, β-tubulin, and one of the hypothetical proteins) were cloned in a prokaryotic expression vector, and the corresponding recombinant proteins were purified and evaluated for the serodiagnosis of TL. The antigens presented sensitivity and specificity values ranging from 95.4 to 100% and 82.5 to 100%, respectively. As a comparative antigen, a preparation of Leishmania extract showed sensitivity and specificity values of 65.1 and 57.5%, respectively. The present study has enabled the identification of proteins able to be employed for the serodiagnosis of TL.
UR - http://www.scopus.com/inward/record.url?scp=84945548314&partnerID=8YFLogxK
U2 - 10.1128/CVI.00465-15
DO - 10.1128/CVI.00465-15
M3 - Article
C2 - 26376929
AN - SCOPUS:84945548314
SN - 1556-6811
VL - 22
SP - 1187
EP - 1196
JO - Clinical and Vaccine Immunology
JF - Clinical and Vaccine Immunology
IS - 11
ER -